Answers are grounded in this paper and cite their sources.
The incidence of both community-acquired and nosocomial fungal infections has significantly increased over the past several decades. The major factors for this increase are a heightened use of antibiotics, a growing population of the elderly and of immunocompromised patients as a result of HIV, cancer, and organ transplantation. In this article, we will review the indications, efficacy, and safety of the polyenes, imidazoles, triazoles, and other systemic antifungals in development that are used for systemic fungal infections.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: